Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?

Author(s): Beata Franczyk, Anna Gluba-Brzózka*, Piotr Bartnicki, Maciej Banach, Jacek Rysz

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 20 , 2017

Become EABM
Become Reviewer
Call for Editor


Background: Cardiovascular morbidity and mortality of dialysis patients are major problems in this group of patients.

Methods: The purpose of this study was also to evaluate whether any of the studied markers are better than troponin in early detection of the occurrence of ventricular arrhythmias and prolongation of QT interval. This study included 45 patients undergoing hemodialysis. ECG Holter and echocardiographic examination were performed before and after dialysis. The concentrations of markers: copeptin, GDF-15, HFABP and troponin were measured with the use of ELISA tests.

Results: We observed significantly higher QT (p=0.004), QTc (0.018), right atrium volume (p=0.006) and concentrations of copeptin (p<0.0001) and H-FABP (p<0.0001) as well as smaller left atrium volume (p<0.0001) and width of inferior vena cava (p<0.0001) after dialysis than before it. Significantly longer QT and higher copeptin levels were seen in patients with ventricular arrhythmia. A trend between the increase in copeptin concentration and H-FABP level and the presence of ventricular arrhythmias was also noted.

Conclusion: Generally, we failed to find any strong predictor of post-dialysis ventricular arrhythmia or the prolongation of QT, however, it seems that copeptin may have prognostic value, but this has to be analyzed in large studies.

Keywords: Cardiac dysfunction, hemodialysis, ventricular arrhythmias, biomarkers, copeptin, GDF-15, HFABP.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [3024 - 3033]
Pages: 10
DOI: 10.2174/1381612823666170508152501
Price: $65

Article Metrics

PDF: 27